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Background: Health economic evaluations support health-care decision-making 
by providing information on the costs and consequences of health interventions. 
No universally accepted methodology exists for modelling effectiveness and cost-
effectiveness of interventions designed to close treatment gaps for headache 
disorders in countries of Europe (or elsewhere). Our aim here, within the 
European Brain Council’s Value-of-Treatment project, was to develop headache-
type-specific analytical models to be applied to implementation of structured 
headache services in Europe as the health-care solution to headache. 
Methods: We developed three headache-type-specific decision-analytical 
models using the WHO-CHOICE framework and adapted these for three 
European Region country settings (Luxembourg, Russia and Spain), diverse in 
geographical location, population size, income level and health-care systems and 
for which we had population-based data. Each model compared current 
(suboptimal) care vs target care (delivered in accordance with the structured 
headache services model). Epidemiological and economic data were drawn from 
studies conducted by the Global Campaign against Headache; data on efficacy of 
treatments were taken from published randomized controlled trials; assumptions 
on uptake of treatments, and those made for Healthy Life Year (HLY) 
calculations and target-care benefits, were agreed with experts. We made 
annual and 5-year cost estimates from health-care provider (main analyses) and 
societal (secondary analyses) perspectives (2020 figures, euros). 
Results: The analytical models were successfully developed and applied to each 
country setting. Headache-related costs (including use of health-care resources 
and lost productivity) and health outcomes (HLYs) were mapped across 
populations. The same calculations were repeated for each alternative (current 
vs target care). Analyses of the differences in costs and health outcomes 
between alternatives and the incremental cost-effectiveness ratios are presented 
elsewhere.  
Conclusions: This study presents the first headache-type-specific analytical 
models to evaluate effectiveness and cost-effectiveness of implementing 
structured headache services in countries in the European Region. The models 
are robust, and can assist policy makers in allocating health budgets between 
interventions to maximize the health of populations. 
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Headache disorders, principally migraine, tension-type headache (TTH) and 
medication-overuse headache (MOH), are responsible for 5.4% of all disability in 
the world and were the cause in 2019 of an estimated 46.6 million years lived 
with disability (YLDs) globally [1,2]. Most (88.2%) of these were attributable to 
migraine [3], recognized in successive iterations of the Global Burden of Disease 
(GBD) study as the world’s second leading cause of disability [1,4-6]. Because 
disability leads to lost productivity, headache disorders have substantial financial 
impact. Each million of the population in Europe loses an estimated 400,000 
days from work or school every year to migraine alone, while the estimated cost 
of headache disorders in Europe, due in the main to lost productivity, is well in 
excess of €100 billion per year [7]. 
Effective treatments exist for these disorders [8] but are under-utilized, largely 
because, in all countries, health-care systems fail to provide them [9]. The 
reasons are complex and not for discussion here, but they have their roots in 
health policies that trenchantly deny headache disorders the priority they clearly 
deserve [10] in view of the ill health they cause [1-6]. The solution – structured 
headache services – has been proposed [9], but its adoption will depend – 
rightly in a universal context of competition for resources – on economic 
evidence of cost-effectiveness, value and return on investment. 
EBC’s Value-of-Treatment project  
In 2015, the European Brain Council (EBC) initiated its Value-of-Treatment (VoT) 
project, building on the success of its Cost of Brain Disorders database [11,12]. 
VoT set out to identify obstacles, pinch-points and dead-ends in the “patient’s 
journey” through each of nine common mental and neurological diseases, 
including headache, then specify remedies and, in its ultimate purpose, assess 
the value of improvements made in line with these remedies [13]. 
In the headache case, the inefficiencies and failures of the care pathway are 
described in previous manuscripts [9,14]. Structured headache services as the 
specific remedy are based in primary care in order to provide sufficient reach, 
with recourse to specialist services at second and third levels for the relatively 
few patients needing these [9]. Implementation requires educational supports at 
all levels, for the general public as well as health-care providers, which are built 
into the model [9]. With these supports, only about one third of people with 
headache should need professional care at any level, and primary care should 
effectively manage about 90% of these [9]. 
As for value, structured headache services reaching all who may benefit will be 
costly to implement. The up-front investment will be substantial, but so is the 
expected recovery of lost health [9]. Our aim here, through decision-analytical 
modelling, is to generate the required evidence of value needed to influence 
policy.  
No universally accepted methodology exists for modelling effectiveness and cost-
effectiveness of service-delivery interventions designed to close headache 
treatment gaps. This paper reports our development of methods and their use. 
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We describe current care and the treatment management plan to achieve target 
care, the types of intervention, and the coverage and uptake estimates used in 
three headache-type-specific decision-analytical models. We explain how we 
calculate economic and health outcomes, and report the key results of applying 
the three analytical models to population data from three paradigmatic countries 
in the European Region, including healthy life years (HLYs) gained and cost 
differences when changing from current to target care. The full economic 
analyses are reported elsewhere [15]. 
METHODS 
We selected three countries of the World Health Organization (WHO) European 
Region: Luxembourg, Russia and Spain, diverse in geographical location, 
population size, level of income and health-care systems. Important in these 
choices was that, for each, we had population-based data to support the 
analyses [16-18]. 
We developed three separate headache-type-specific decision-analytical models 
from an earlier exercise using the WHO-CHOICE framework [19], and simulated 
outcomes for the populations of 18-65-year-olds with migraine, TTH or MOH. In 
each model, two alternatives were compared: current (suboptimal) care vs 
target care delivered in accordance with the structured headache services model 
(see Figures 2-4). We made annual and 5-year cost estimates from health-care 
provider (main analyses) and societal perspectives (secondary analyses) (2020 
figures, euros). We expressed effectiveness as HLYs gained and cost-
effectiveness as incremental cost-effectiveness ratios (ICERs) (cost to be 
invested/HLY gained). We applied WHO thresholds to establish cost-
effectiveness: interventions costing <3x gross domestic product (GDP) per 
capita per HLY were deemed cost-effective, those costing <1x GDP per capita 
were highly cost-effective [20]. In comparisons of current vs target care, we 
made the assumptions that implemented structured services with provider-
training would achieve higher coverage (the proportion of people in need of a 
treatment who receive it), and consumer-education would lead to better 
adherence (the proportion who use a treatment effectively, having received it), 
in each case, conservatively, by 50% of the gap between current and ideal. 
Economic outputs included direct costs (resources sunk into health-care 
provision) and indirect costs (lost work productivity [see secondary analyses]). 
We performed sensitivity analyses with regard to how much lost productivity 
might be recovered to test robustness of the model. 
Decision-analytical models: treatment management 
plan, selection of interventions and medicines uptake 
We developed and applied the three headache-type-specific decision-analytical 
models to each country setting. For each alternative (current and target care), 
we adopted a core set of drug interventions, focusing on those included in Linde 
et al [19]. Among these were first-line (simple analgesics: eg, acetylsalicylic acid 
(ASA) 1,000 mg) and second-line medications (eg, sumatriptan 50 mg) for acute 
treatment of attacks, with the assumption that the latter would be used only by 
non-responders to the former in a stepped-care treatment paradigm [8]. We 
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also included preventative drugs (eg, amitriptyline 100 mg daily) to be used by 
those with ≥3.5 headache days/month. For target care, we added to the model 
the expected consequences of consumer education (posters and leaflets in 
pharmacies explaining how to acquire and make best use of these medications) 
and of health-care provider training. 
The treatment plans for the three headache types are described in Tables 1-3. 
We estimated uptake (%) of each treatment in current care (Ucc) in each of the 
three settings according to coverage and adherence. We took coverage data 
from Global Campaign studies [17,18], including the Eurolight project [16,21], 
and followed Linde et al [19] on adherence (see Tables 1-3). For target care, we 
calculated predicted uptake (Utc) as {[(100 ‒ Ucc)/2] + Ucc}%. All details on the 
data used and assumptions made to calculate uptake are in Tables 1-3. We 
adjusted estimates of efficacy from published clinical trials by reference to 
uptake, better to reflect effectiveness in the real world. 
Economic outcomes: use of resources and lost 
productivity according to treatment management plan  
Use of resources and lost productivity data were taken or extrapolated from 
different sources (Tables 1-3) [7,8,21,22]. Unit costs for health-care resources 
(medicines, consultations, examinations) [19] and daily wages [23] are reported 
in Appendix 1. We actualised costs in euros to 2020 values using the appropriate 
consumer price index [24]. At population level, the relationship between lost 
productivity and headache-attributed disability is complex (people are variably 
influenced by a number of extraneous and sometimes random factors) [25]. We 
therefore performed sensitivity analyses with regard to this. In our baseline 
sensitivity scenario, all lost productivity was explained by headache-attributed 
disability, whereas, in an alternative scenario, measurable disability accounted 
for only 20% of lost productivity. 
Health outcomes: epidemiological data, disability, and 
estimation of intervention effectiveness 
We ran a population model for the two alternatives (current vs target care) over 
one- and five-year time frames to estimate total HLYs lived by the populations in 
each country in each alternative. The differences between these two simulations 
represented the population-level health gain (HLYs gained) from the intervention 
relative to current care. Epidemiological data were sourced from Global 
Campaign surveys performed in the three countries [1] (see Table 4). 
We applied separate disability weights (DWs) (health state valuations on a 0–1 
scale, where 1 equals full health) to the times spent in the ictal state (within-
attack) and interictal state (between attacks, but susceptible). Ictal DWs (0.441 
for migraine, 0.037 for TTH and 0.217 for MOH) were available from GBD2015 
[26; Table 4]. For interictal DW in each disorder, to reflect interictal disability 
[27], we used the lowest possible weighting of 0.01 and applied it only to those 
with high-frequency attacks (>3.5/month). For migraine and TTH, we calculated 
headache-attributed disability at individual level in YLDs as the product of 
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proportion of time in ictal state (pTIS: itself estimated as a product of attack 
frequency (F) and mean duration), with and without intervention, and the DW 
for the disorder in question. For MOH, we assumed pTIS was equal to 
(days/month affected)/30. To estimate disability at population level, we 
multiplied the means of these values by prevalence of the respective disorder. 
Epidemiological data [16,17,18], including attack frequencies and durations 
[19], and DWs [26] for the different models are summarised in Table 4.  
We modelled treatment effect as reduction in pTIS, adopting the universal 
outcome measure previously developed for this purpose [28] but, since this was 
a population-level analysis, expressing effect in terms of HLYs gained rather than 
hours lived with disability (HLDs) averted. Accordingly, for acute medicines, we 
used the clinical endpoint of “sustained headache relief” (SHR), defined as 
reduction in headache intensity from moderate or severe to mild or none within 
2 hours and without recurrence or further medication during 24 hours. We 
assumed baseline headache was always at least moderate, and that mild and no 
pain were not associated with disability. SHR therefore implied full recovery of 
the remaining hours of the attack that would have been spent with disability 
[19,28]. We assumed that treatment was taken at attack onset, so that hours 
recovered per treated attack = D-2, where D = expected attack duration in 
hours [19,28]. Thus: 
• pTISuntreated = D * F  
• pTIStreated = [(D-2)/D * (pFtreated * pSHR)] + {D * [(1- (pFtreated * pSHR)]} 
• reduction in pTIS = pTISuntreated – pTIStreated 
where: F = attack frequency; pFtreated = proportion treated; pSHR = efficacy 
expressed as proportion of treated attacks with SHR. 
We assessed the effect of acute management and its combination in high-
frequency cases with preventative drugs (modifying F), together with the 
potential effects of provider training on treatment coverage (modifying pFtreated) 
and of consumer education on adherence (modifying pFtreated and pSHR). Data on 
efficacy (from randomized controlled trials) and uptake are listed in Table 5 [30-
35]. For MOH we assumed success in 85% of treated cases, with reversion to 
other types of headache (ie, 2/3 to migraine and 1/3 to TTH); the other 15% 
would remain unchanged, but off medications. 
We estimated effect per person treated per time period T years as follows: 
• YLDsuntreated = T * {(pTISuntreated * ictal DW) [+ (1 – [pTISuntreated * interictal 
DW]) in high-frequency cases]};  
• YLDstreated = T * {(pTIStreated * ictal DW) [+ (1 – [pTIStreated * interictal 
DW]) in high-frequency cases]}; 
• HLYs gained = YLDsuntreated – YLDstreated.  
In the case of MOH, HLYs gained were offset according to the assumption that 
treatment success implied reversion to migraine (2/3) or TTH (1/3), with HLYs 
lost in accordance with these disorders treated. 
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HLYs gained per person under a particular treatment plan were equal to the sum 
of the gains from each treatment multiplied by the probability of having each 
treatment. HLYs gained in the population were equal to HLYs gained per person 
multiplied by the prevalence of the disorder. Assumptions adopted when 
calculating the health effects are summarised in Table 5. 
RESULTS 
Here we set out results for the three countries in terms of headache-related 
costs (including use of health-care resources and lost productivity) and health 
outcomes (HLYs) attached to each alternative (current vs target care) only to 
demonstrate how the models worked. Analyses of the differences in costs and 
health outcomes between alternatives and the incremental cost-effectiveness 
ratios are presented elsewhere [15]. 
Decision-analytical models: treatment management plan 
and selection of interventions 
Figures 2-4 represent the separate decision analytical models developed and 
applied to the three country settings. The complete lists of medications, 
corresponding uptake estimates and assumptions made according to the 
different management plans (current and target alternatives) for the three 
headache types are set out in Tables 1-3.  
Economic outcomes 
Tables 6-8 report the economic outcomes attached to different treatment plans 
for each headache type and each country. A breakdown of the different 
headache costs is reported for types of medication, types of consultation, 
examinations and lost productivity. The same calculations are repeated for each 
alternative (current vs target care) and for the differences between these. For 
MOH, summary numbers for health-care costs and lost productivity are provided 
(Table 8), whereas we refer to Tables 6 and 7 (target care scenario) for costs 
incurred by reversion to migraine or TTH. Two separate sets of data are provided 
for one-year and five-year time frames.  
For example, for the estimated 18,122,512 Russians with migraine (Table 6): 
• current care required 303,241,487 euros invested in health care over one 
year, whereas 
• target care (with consumer education and health-care provider training) 
would require 575,883,120 euros invested in health care over one year. 
Health outcomes 
Table 4 reports calculated headache-attributed disabilities at individual level. 
Tables 9-11 report annual HLYs potentially gained by each element of the 
proposed treatment plan for each headache type in each country. The same 
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calculations are again repeated for each alternative (current vs target care) and 
for the differences between these. The population-level effect on health of the 
intervention strategies for target care, through reduced pTIS (achieved through 
SHR and/or reduced attack frequency), is quite substantial.  
For example, for all Russians with migraine: 
• current care gained an estimated 158,406 HLYs, whereas 
• target care (with consumer education and health care professional 
training) would secure 322,115 HLYs gained (163,709 more than current 
care; Table 9). 
DISCUSSION 
This study presents the first headache-type-specific analytical models for 
comparing the effectiveness and cost-effectiveness of implemented structured 
headache services across European Region country settings. The models linked 
direct costs (resources sunk into health-care provision) and indirect costs (lost 
work productivity) with health outcomes (in terms of HLYs). While the literature 
does provide a framework to assess population-level cost-effectiveness of 
evidence-based migraine treatments in low- and middle-income countries [19], 
data are very scarce on costs and effects of introducing headache services 
enhancing treatment delivery through a better-defined care pathway [9]. The 
methodology was successful, bringing together observed data for current care 
and estimates for target care. The flexibility of the models allowed 
measurements of the benefits, in people with different headache types, of care 
improvements achieved through implementing structured services in different 
countries. 
The countries included – Luxembourg, Russia and Spain – were diverse in terms 
of geographical location, population size, level of income and organisation of 
their health-care systems. For example, Luxembourg was chosen because their 
health-care system is perceived as one of the best in Europe [36]. It has a high 
standard of state-funded health care covering every citizen, each having the 
right to choose their doctor, specialist and hospital. In Russia, although the 
health service is free to all, a complex compulsory medical insurance system 
coupled with low wages for doctors and nurses means that demands for out-of-
pocket payments remain a pervasive and discouraging problem. Lastly, Spain 
offers free, universal health care to anyone resident, but the system is 
decentralised across the country’s 17 autonomous regions, so that quality of 
care, and access to specialist procedures or units, vary across regions. 
The population and costing models rest upon a series of best estimates, 
including the expected patterns of resource use and intervention efficacy. Data 
to support these in each of the three countries were sourced from population-
based studies in Russia [17,18] and the Eurolight project for Luxembourg and 
Spain [16]. Unfortunately, in Eurolight, participation proportions were 
suboptimal and samples might not be truly representative [36]. Participants 
were not asked about formulations of acute medicines, and the numbers of 
doses were estimated conservatively. For preventative medicines, it was 
assumed that recommended doses were used [8,19]. 
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In addition, effectiveness data were drawn from published controlled trials, 
which did not always include the countries in question. All findings might also be 
sensitive to assumptions made in the costing model, and to possible variations in 
the national statistics applied (see Table 4).  
Even though the indirect costs of migraine and MOH dominate the direct costs, 
productivity gains and lost-time costs were not taken into consideration in our 
main analyses because no internationally agreed approach is yet available to 
measure these satisfactorily [7,11]. However, in our sensitivity analyses, we 
used the human capital approach as the most common method for estimating 
the economic value of employee productivity, assuming that it is equal to gross 
earnings [38]. This allowed us to re-run the models from the broader societal 
perspective, covering both health-care provider costs and those due to lost 
productivity. 
A major difficulty lay in the relationship between headache-attributed disability, 
estimated from DWs generated in GBD2015, and headache-attributed lost work 
productivity. A strong correlation was intuitively expected. In our baseline 
scenario, we assumed that lost productivity was fully explained by headache-
attributed disability: ie, reductions in disability would bring commensurate 
reductions in lost productivity. This may not be so at population level because, 
as mentioned earlier, people are variably influenced by a number of extraneous 
and sometimes random factors [26]. The sensitivity analyses showed that 
varying the proportion of lost productivity recovered had a major impact on 
economic estimates. This was expected, because predicted savings in work 
productivity greatly exceeded the investments in health care estimated to be 
needed to achieve these savings. Nevertheless, in a conservative scenario, 
where we assumed that remedying disability would recover only 20% of the lost 
productivity attributed to it, the intervention remained cost-effective in all 
models and cost-saving in Luxembourg. Furthermore, at individual level 
(relevant in the context of treatment), the extraneous factors are mostly 
constant, meaning a simpler and closer relationship was likely [25]. 
CONCLUSION  
Despite these limitations, the study delivered robust models, with detailed results presented 
in the next paper in this series [15]. The models should greatly assist local health-policy 
makers, across Europe and very probably elsewhere, in allocating fixed health budgets 
between interventions to maximise health in society. Health-care systems vary widely even 
within the European Region, and certainly outside it, but the analytical models should be 
applicable to any that adopt and fully implement the services model [9]. Widely different 
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Figure 1: Template for structured headache services supported by 
educational initiatives, and expected patient flows (as described in [9]: 
structured headache services are based in primary care and supported by 
specialist care; educational initiatives are aimed at health-care providers to 
improve competence at their level, and at the public to promote self-care and 
effective use of both over-the-counter (OTC) drugs and headache services; 
pharmacists advise on use of OTC and other drugs, discouraging overuse, and 
on use of headache services; within these services, everyone with headache 
should make best use of OTC drugs; about one third of people with headache 
need professional health care; primary care provides effective management for 






Figure 2: Analytical models for Luxembourg (data are reported in Table 1) 
MIGRAINE current care (estimates derived from 
published data, see treatment plan, Table 1) 
MIGRAINE target care (expert assumptions) 
 
 
TTH current care (estimates derived from published 
data, see treatment plan, Table 1) 
TTH target care (expert assumptions) 
 
 
MOH current care (estimates derived from 
published data, see treatment plan, Table 1) 

























50% of 91.9% = 46.0%
stepped care 18.4% 
we assumed 
20% of 91.9% = 18.4% 
migraine prophylaxis 27.6%
we assumed 
30% of 91.9% = 27.6%
population 













[{100% - 58.2%}/2] 
+ 58.2%) = 79.1%
acute medications 76.7% 
we assumed 
97% of 79.1% = 76.7% 
prophylaxis 2.5% 
we assumed 
3% of 78.0% =  2.5% 
population 









[(100 - 0%)/2] + 0% 
= 50%
we asumed 42.5% revert 
to migraine (28.3%) 
or TTH (14.2%)
we assumed 7.5% remain 
unchanged but off 
medication
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Figure 3: Analytical models for Russia (data are reported in Table 2) 
MIGRAINE current care (estimates derived from 
published data, see treatment plan, Table 1) 
MIGRAINE target care (expert assumptions) 
 
 
TTH current care (estimates derived from 
published data, see treatment plan, Table 1) 
TTH target care (expert assumptions) 
 
 
MOH current care (estimates derived from 
published data, see treatment plan, Table 1) 

























50% of 82.0% = 41.0%
stepped care 16.4% 
we assumed 
20% of 82.0% = 16.4% 
migraine prophylaxis 24.6%
we assumed 
30% of 82.0% = 24.6%
population 












[(100% - 55.6%)/2] + 
55.6% = 78.0%
acute medications 75.5% 
we assumed 
97% of 78.0% = 75.5% 
prophylaxis 2.5% 
we assumed 
3% of 78.0% =  2.5% 
population 









[(100 - 0%)/2] + 0% 
= 50%
we asumed 42.5% revert
to migraine (28.3%) 
or TTH (14.2%)
we assumed 7.5% remain 
unchanged but off 
medication
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Figure 4: Analytical models for Spain (data are reported in Table 3) 
MIGRAINE current care (estimates derived from 
published data, see treatment plan, Table 1) 
MIGRAINE Target care (expert assumptions) 
 
 
TTH current care (estimates derived from 
published data, see treatment plan, Table 1) 
TTH Target care (expert assumptions) 
 
 
MOH current care (estimates derived from 
published data, see treatment plan, Table 1) 

























50% of 94.3% = 47.2%
stepped care 18.9% 
we assumed 
20% of 94.3% = 18.9% 
migraine prophylaxis 28.3%
we assumed 
30% of 94.3% = 28.3%
population 













[(100% - 69.6%)/2] + 
69.6% = 84.8%
acute medications 75.5% 
we assumed 
97% of 84.8% = 82.3% 
prophylaxis 2.5% 
we assumed 
3% of 84.8% =  2.5% 
population
(18-65 yrs old) 
with MOH
treatment coverage 0% population





[(100 - 0%)/2] + 0% = 
50%
we asumed 42.5% revert 
to migraine (28.3%) 
or TTH (14.2%)
we assumed 7.5% remain 

















Migraine 83.8 91.9 Current care: 72.1% migraine non-specific; 7.1% migraine specific; 4.6% 
migraine prophylaxis (see treatment plan below) 
Target care: We assumed that structured services with consumer education 
and provider training enhances coverage and adherence so that uptake is 
increased by 50% of current deficit: medicines uptake = [{100% - 
83.8%}/2] + 83.8 %) = 91.9% 
TTH 58.2 79.1 Current care: 58.2% acute medications; 0% TTH prophylaxis (see 
treatment plan below) 
Target care: We assumed as above: medicines uptake = [{100% - 
58.2%}/2] + 58.2%) = 79.1% 
MOH 0 50.0 Current care: 0% treated 
Target care: We assumed that structured services with consumer education 
and provider training enhances treatment coverage and adherence so that 
proportion withdrawn from medicines overuse is increased by 50% of current 
deficit: withdrawal = [{100 - 0%}/2] + 0%) = 50.0% 
TREATMENT PLAN 
A. Acute management (non-specific drugs) 
Simple 
analgesics 
(eg, ASA 1 g) 
Migraine 72.1 46.0 Current care: from Eurolight data [21] 
Target care: With consumer education and provider training, treatment with 
simple analgesics alone is used by or offered to 50% (expert assumption), 
with uptake = 46.0% (50% of 91.9%) 
TTH 55.6 76.7 Current care: from Eurolight data [21] 
Target care: With consumer education and provider training, treatment with 
simple analgesics alone is used by or offered to 97% (expert assumption), 
with uptake 76.7% (97% of 79.1%) 
MOH 0 0 Not applicable to MOH care 
B. Acute management (specific drugs) 





Target care: With provider training, treatment with specific drugs alone is 
offered to 0% (expert assumption) 
TTH 0 0 Not applicable to TTH care 
MOH 0 0 Not applicable to MOH care 
C. Acute stepped-care management 
ASA 1 g + 
sumatriptan 
50 mg 
Migraine 0 18.4 Current care: not included in current care 
Target care: With provider training, acute stepped-care management is 
offered to 20% (expert assumption), with uptake = 18.4% (20% of 91.9%) 
TTH 0 0 Not applicable to TTH care 
MOH 0 0 Not applicable to MOH care 
D. Prophylaxis + acute management 
Amitriptyline 
100 mg/day 
+ ASA 1 g + 
sumatriptan 
50 mg 
Migraine 4.6 27.6 Current care: from Eurolight data [21] 
Target care: With provider training, prophylaxis + acute stepped-care 
management is offered to 30% (expert assumption), with uptake = 27.6% 
(30% of 91.9%) 
TTH 0 2.4 Current care: not included in current care 
Target care: With provider training, prophylaxis + acute care management 
is offered to 3% (expert assumption), with uptake = 2.4% (3% of 79.1%) 
MOH 0 0 Not applicable to MOH care 
Consultations and investigations 
Doctor visits 
(year 1) 
Migraine 25.1 50.0 Current care: 25.1% with migraine had seen a doctor (Eurolight data [21]), 
of whom 19.3% had seen a GP and 5.8% a specialist. We assumed 2 visits in 
either case. 
Target care: With consumer education, 50% see a doctor (expert 
assumption based on estimated need for professional care). 
Note that in the model those who see a specialist would see a GP first. 
TTH 9.4 2.25 Current care: 9.4% with TTH had seen a doctor (Eurolight data [21]), of 
whom 6.9% had seen a GP and 2.5% a specialist. We assumed 2 visits in 
either case.  
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Target care: With consumer education, 3% (Stovner 2007 [38]) x 75% = 
2.25% see a specialist and none see a GP (expert assumption based on 
estimated need for professional care).  
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2% with MOH had seen a doctor (Eurolight data [21]), of 
whom 21.6% had seen a GP and 29.6% a specialist. We assumed 2 visits in 
either case.  
Target care: With consumer education, 100% see a doctor (expert 
assumption based on estimated need for professional care). 
Note that those who see a specialist would see a GP first. 
GP visits  Migraine 19.3 45.0 Current care: 19.3% had seen a GP (Eurolight data [21]) 
Target care: With consumer education, 45.0% (90% of 50%) see a GP (we 
assumed 2 visits in a year) 
TTH 6.9 0 Current care: 6.9% had seen a GP (2 times in a year) (Eurolight data [21]) 
Target care: Chronic TTH is difficult to treat, so we assumed that all should 
go to levels 2 or 3 (ie, "specialists"). 
Note that those who see a specialist would see a GP first. 
MOH 21.6 100 Current care: 21.6% had seen a GP (2 times in a year) (Eurolight data 
[21]) 
Target care: With consumer education, 100% see a GP (we assumed 2 
visits in a year) 
Specialist 
visits 
Migraine 5.8 5.0 Current care: 5.8% had seen a specialist (2 times in a year) 
Target care: With consumer education and provider training, 5.0% (10% of 
50%) see a specialist (we assumed 2 visits in a year) 
TTH 2.5 2.25 Current care: 2.5% had seen a specialist (2 times in a year) 
Target care: With consumer education and provider training, 2.25% see a 
specialist (we assumed 2 visits in a year) 
MOH 29.6 100 Current care: 29.6 % saw a GP (2 times in a year) 
Target care: With consumer education and provider training, 100% see a 




Migraine 8.5 1.0 Current care: All those seeing a specialist had MRI (one in a year) 




TTH 1.0 0.5 Current care: 1% had an MRI 
Target care: We assumed 0.5% have MRI examination (one in a year) – 
half the current estimate 
MOH 0 0 Current care: Nobody had an MRI 
Target care: Nobody has an MRI 
Doctor visits  
(years 2-5) 
Migraine 24.6 50.0 Current care: 24.6% with migraine had seen a doctor (Eurolight data [21]), 
of whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 50% see a doctor (expert 
assumption based on estimated need for professional care) 
TTH 9.4 2.25 Current care: 9.4% with TTH had seen a doctor (Eurolight data [21]), of 
whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 3% (Stovner 2007 [38]) x 75% = 
2.25% see a doctor (expert assumption based on estimated need for 
professional care).  
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2% with MOH had seen a doctor (Eurolight data [21]), of 
whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 100% see a doctor 
GP visits  Migraine 24.6 50.0 Current care: 24.6% saw a GP. We assumed 2 visits each year. 
Target care: With consumer education, 50% see a GP. We assumed 2 visits 
each year. 
TTH 9.4 0 Current care: 9.4% saw a GP. We assumed 2 visits each year. 
Target care: Chronic TTH is difficult to treat, so we assumed that all should 
go to levels 2 or 3 (ie, "specialists"). 
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2 % saw a GP. We assumed 2 visits each year. 
Target care: With consumer education, 100% see a GP. We assumed 2 
visits each year. 
Specialist 
visits 
Migraine 0 0 Current care: No visits after year 1 
Target care: No visits after year 1 
TTH 0 2.25 Current care: No visits after year 1 
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Target care: With consumer education and provider training, 2.25% see a 
specialist (we assumed 2 visits in a year). 
MOH 0 0 Current care: No visits after year 1 




Migraine 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
TTH 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
MOH 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
Lost productivity We assumed that lost work productivity was correlated with disease-attributed disability, and reduced disability 
would bring reduced lost productivity. In our baseline scenario, all lost productivity was explained by disease-
attributed disability. 
Days lost 
from work in 
12 months 
Migraine 7.6 2.4 Current care: Based on Eurolight data [16] 
Target care: We assumed 69% decrease in lost productivity (equal to the 
gain in HLYs reported for migraine [see Table 4]): 7.6-(7.6*0.69) = 2.4 
days. 
 TTH 3.2 1.0 Current care: Based on Eurolight data [16] 
Target care: We assumed 76% decrease in lost productivity (equal to the 
gain in HLYs reported for TTH [see Table 4]): 3.2-(3.2*0.76 ) = 1.0 days.  
 MOH 22.8 7.1 (if revert 
to migraine); 
5.5 (if revert 
to TTH) 
Current care: Based on Eurolight data [16] 
Target care:  
For individuals reverting to migraine, we assumed 69% decrease in lost 
productivity (equal to the gain in HLYs reported for migraine [see Table 4]): 
22.8-(22.8*0.69 ) = 7.1 days 
For individuals reverting to TTH, we assumed 76% decrease in lost 
productivity (equal to the gain in HLYs reported for TTH [see Table 4]): 22.8-





Table 2: Treatment uptake, use of resources and lost productivity according to treatment management plan 
(Russia) 











Migraine 64.7 82.0 Current care:  
63.5% migraine non-specific; 0.5% migraine specific; 0.7% migraine 
prophylaxis  
Target care: We assumed that structured services with consumer education 
and provider training enhances coverage and adherence so that overall 
uptake is increased by 50%; medicines uptake = [{100% - 64.7%}/2] + 
64.7%) = 82.0% 
TTH 55.6 77.8 55.6% (acute medications) TTH; 0% TTH prophylaxis (see treatment plan 
below) 
Target care: We assumed as above; medicines uptake = [{100% - 
55.6%}/2] + 55.6%) = 77.8% 
MOH 0 50.0 Current care: 0% treated 
Target care: We assumed that structured services with consumer education 
and provider training enhances treatment coverage and adherence so that 
proportion withdrawn from medicines overuse is increased by 50% of current 
deficit: withdrawal = [{100 - 0%}/2] + 0%) = 50% 
TREATMENT PLAN 
A. Acute management (non-specific drugs) 
Simple 
analgesics 
(eg, ASA 1 g) 
Migraine 63.5 41.0 Current care: from Eurolight data [21] 
Target care: With provider training, treatment with simple analgesics alone 
is offered to 50% (expert assumption), with uptake = 41.0% (50% of 
82.0%) 
TTH 55.6 75.5 Current care: from Eurolight data [21] 
Target care: With provider training, treatment with simple analgesics alone 
is offered to 97% (expert assumption), with uptake = 75.5% (97% of 
77.8%) 
MOH 0 0 Not applicable to MOH care 
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B. Acute management (specific drugs) 
Sumatriptan 
50 mg 
Migraine 0.5 0 Current care: from Eurolight data [21] 
Target care: With provider training, treatment with specific drugs alone is 
offered to 0% (expert assumption) 
TTH 0 0 Not applicable to TTH care 
MOH 0 0 Not applicable to MOH care 
C. Acute stepped-care management 
ASA 1 g + 
sumatriptan 
50 mg 
Migraine 0 16.4 Current care: not included in current care 
Target care: With provider training, acute stepped-care management is 
offered to 20% (expert assumption), with uptake = 16.4% (20% of 82.0%) 
TTH 0 0 Not applicable to TTH care 
MOH 0 0 Not applicable to MOH care 
D. Prophylaxis + acute management 
Amitriptyline 
100 mg/day 
+ ASA 1 g + 
sumatriptan 
50 mg 
Migraine 0.7 24.6 Current care: from Eurolight data [21] 
Target care: With provider training, prophylaxis + acute stepped-care 
management is offered to 30% (expert assumption), with uptake = 24.6% 
(30% of 82.0%) 
TTH 0 2.3 Current care: not included in current care 
Target care: With provider training, prophylaxis + acute care management 
is offered to 3% (expert assumption), with uptake = 2.3% (3% of 77.8%) 
MOH 0 0 Not applicable to MOH care 
Consultations and investigations 
Doctor visits 
(year 1) 
Migraine 25.1 50.0 Current care: 25.1% with migraine had seen a doctor (Eurolight data [21]), 
of whom 19.3% had seen a GP and 5.8% a specialist. We assumed 2 visits in 
either case. 
Target care: With consumer education, 50% see a doctor (expert 
assumption based on estimated need for professional care). 
Note that in the model those who see a specialist would see a GP first. 
TTH 9.4 2.25 Current care: 9.4% with TTH had seen a doctor (Eurolight data [21]), of 
whom 6.9% had seen a GP and 2.5% a specialist. We assumed 2 visits in 
either case.  
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Target care: With consumer education, 3% (Stovner 2007 [38]) x 75% = 
2.25% see a specialist and none see a GP (expert assumption based on 
estimated need for professional care).  
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2% with MOH had seen a doctor (Eurolight data [21]), of 
whom 21.6% had seen a GP and 29.6% a specialist. We assumed 2 visits in 
either case.  
Target care: With consumer education, 100% see a doctor (expert 
assumption based on estimated need for professional care). 
Note that those who see a specialist would see a GP first. 
GP visits  Migraine 19.3 45.0 Current care: 19.3% had seen a GP (Eurolight data [21]) 
Target care: With consumer education, 45.0% (90% of 50%) see a GP (we 
assumed 2 visits in a year) 
TTH 6.9 0 Current care: 6.9% had seen a GP (2 times in a year) (Eurolight data [21]) 
Target care: Chronic TTH is difficult to treat, so we assumed that all should 
go to levels 2 or 3 (ie, "specialists"). 
Note that those who see a specialist would see a GP first. 
MOH 21.6 100 Current care: 21.6% had seen a GP (2 times in a year) (Eurolight data 
[21]) 
Target care: With consumer education, 100% see a GP (we assumed 2 
visits in a year) 
Specialist 
visits 
Migraine 5.8 5.0 Current care: 5.8% had seen a specialist (2 times in a year) 
Target care: With consumer education and provider training, 5.0% (10% of 
50%) see a specialist (we assumed 2 visits in a year) 
TTH 2.5 2.25 Current care: 2.5% had seen a specialist (2 times in a year) 
Target care: With consumer education and provider training, 2.25% see a 
specialist (we assumed 2 visits in a year) 
MOH 29.6 100 Current care: 29.6 % saw a GP (2 times in a year) 
Target care: With consumer education and provider training, 100% see a 




Migraine 8.5 1.0 Current care: All those seeing a specialist had MRI (one in a year) 




TTH 1.0 0.5 Current care: 1% had an MRI 
Target care: We assumed 0.5% have MRI examination (one in a year) – 
half the current estimate 
MOH 0 0 Current care: Nobody had an MRI 
Target care: Nobody has an MRI 
Doctor visits  
(years 2-5) 
Migraine 24.6 50.0 Current care: 24.6% with migraine had seen a doctor (Eurolight data [21]), 
of whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 50% see a doctor (expert 
assumption based on estimated need for professional care) 
TTH 9.4 2.25 Current care: 9.4% with TTH had seen a doctor (Eurolight data [21]), of 
whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 3% (Stovner 2007 [38]) x 75% = 
2.25% see a doctor (expert assumption based on estimated need for 
professional care).  
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2% with MOH had seen a doctor (Eurolight data [21]), of 
whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 100% see a doctor 
GP visits  Migraine 24.6 50.0 Current care: 24.6% saw a GP. We assumed 2 visits each year. 
Target care: With consumer education, 50% see a GP. We assumed 2 visits 
each year. 
TTH 9.4 0 Current care: 9.4% saw a GP. We assumed 2 visits each year. 
Target care: Chronic TTH is difficult to treat, so we assumed that all should 
go to levels 2 or 3 (ie, "specialists"). 
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2 % saw a GP. We assumed 2 visits each year. 
Target care: With consumer education, 100% see a GP. We assumed 2 
visits each year. 
Specialist 
visits 
Migraine 0 0 Current care: No visits after year 1 
Target care: No visits after year 1 
TTH 0 2.25 Current care: No visits after year 1 
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Target care: With consumer education and provider training, 2.25% see a 
specialist (we assumed 2 visits in a year). 
MOH 0 0 Current care: No visits after year 1 




Migraine 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
TTH 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
MOH 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
Lost productivity We assumed that lost work productivity is correlated with disease-related disability, and reduced disability would 
bring reduced lost productivity. In our baseline scenario, all lost productivity was explained by disease-related 
disability. 
Days lost 
from work in 
12 months 
Migraine 7.6 3.9 Current care: based on Eurolight data [16] 
Target care: we assumed 49% decrease in lost productivity (equal to the 
gain in HLYs reported for migraine [see Table 4]): 7.6-(7.6*0.49) = 3.9 
days. 
 TTH 3.2 1.0 Current care: based on Eurolight data [16] 
Target care: we assumed 68% decrease in lost productivity (equal to the 
gain in HLYs reported for TTH [see Table 4]): 3.2-(3.2*0.68 ) = 1.0 days.  
 MOH 22.8 11.6 (if revert 
to migraine); 
7.3 (if revert 
to TTH) 
Current care: based on Eurolight data [16] 
Target care: for individuals reverting to migraine, we assumed 49% 
decrease in lost productivity (equal to the gain in HLYs reported for migraine 
[see Table 4]): 22.8 - (22.8*0.49) = 11.6 days 
for individuals reverting to TTH, we assumed 76% decrease in lost 
productivity (equal to the gain in HLYs reported for TTH [see Table 4]): 22.8-





Table 3: Treatment uptake, use of resources and lost productivity according to treatment management plan 
(Spain) 











Migraine 88.6 94.3 Current care: 54.5% migraine non-specific + 20.4% migraine specific 
+13.7% migraine prophylaxis = 88.6% (see treatment plan below) 
Target care: We assumed that structured services with consumer education 
and provider training enhances coverage and adherence so that uptake is 
increased by 50% of current deficit: medicines uptake = [{100% - 88.6%}/2] 
+ 88.6%) = 94.3% 
TTH 69.6 84.8 Current care: 69.6% acute medications; 0% TTH prophylaxis (see treatment 
plan below) 
Target care: We assumed as above: medicines uptake [{100% - 69.6%}/2] 
+ 69.6%) = 84.8% 
MOH 0 50.0 Current care: 0% treated 
Target care: We assumed that structured services with consumer education 
and provider training enhances treatment coverage and adherence so that 
proportion withdrawn from medicines overuse is increased by 50% of current 
deficit: withdrawal = [{100 - 0%}/2] + 0%) = 50.0% 
TREATMENT PLAN 
A. Acute management (non-specific drugs) 
Simple 
analgesics 
(eg, ASA 1 g) 
Migraine 54.5 47.2 Current care: from Eurolight data [21] 
Target care: With provider training, treatment with simple analgesics alone is 
offered to 50% (expert assumption), with uptake = 47.2% (50% of 94.3%) 
TTH 69.6 82.3 Current care: from Eurolight data [21] 
Target care: With provider training, treatment with simple analgesics alone is 
offered to 97% (expert assumption), with uptake = 82.3% (97% of 84.8%) 
MOH 0 0 Not applicable to MOH care 
B. Acute management (specific drugs) 





Target care: With provider training, treatment with specific drugs alone is 
offered to 0% (expert assumption) 
TTH 0 0 Not applicable to TTH care 
MOH 0 0 Not applicable to MOH care 
C. Acute stepped care management 
ASA 1 g + 
sumatriptan 
50 mg 
Migraine 0 18.9 Current care: not included in current care 
Target care: With provider training, acute stepped-care management is 
offered to 20% (expert assumption), with uptake = 18.9% (20% of 94.3%) 
TTH 0 0 Not applicable to TTH care 
MOH 0 0 Not applicable to MOH care 
D. Prophylaxis + acute management 
Amitriptyline 
100 mg/day 
+ ASA 1 g + 
sumatriptan 
50 mg 
Migraine 13.7 28.3 Current care: from Eurolight data [21] 
Target care: With provider training, prophylaxis + acute stepped-care 
management is offered to 30% (expert assumption), with uptake = 28.3% 
(30% of 94.3%) 
TTH 0 2.5 Current care: not included in current care 
Target care: With provider training, prophylaxis + acute care management is 
offered to 3% (expert assumption), with uptake = 2.5% (3% of 84.8%) 
MOH 0 0 Not applicable to MOH care 
Consultations and investigations 
Doctor visits 
(year 1) 
Migraine 25.1 50.0 Current care: 25.1% with migraine had seen a doctor (Eurolight data [21]), 
of whom 19.3% had seen a GP and 5.8% a specialist. We assumed 2 visits in 
either case. 
Target care: With consumer education, 50% see a doctor (expert assumption 
based on estimated need for professional care). 
Note that in the model those who see a specialist would see a GP first. 
TTH 9.4 2.25 Current care: 9.4% with TTH had seen a doctor (Eurolight data [21]), of 
whom 6.9% had seen a GP and 2.5% a specialist. We assumed 2 visits in 
either case.  
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Target care: With consumer education, 3% (Stovner 2007 [38]) x 75% = 
2.25% see a specialist and none see a GP (expert assumption based on 
estimated need for professional care).  
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2% with MOH had seen a doctor (Eurolight data [21]), of 
whom 21.6% had seen a GP and 29.6% a specialist. We assumed 2 visits in 
either case.  
Target care: With consumer education, 100% see a doctor (expert 
assumption based on estimated need for professional care). 
Note that those who see a specialist would see a GP first. 
GP visits  Migraine 19.3 45.0 Current care: 19.3% had seen a GP (Eurolight data [21]) 
Target care: With consumer education, 45.0% (90% of 50%) see a GP (we 
assumed 2 visits in a year) 
TTH 6.9 0 Current care: 6.9% had seen a GP (2 times in a year) (Eurolight data [21]) 
Target care: Chronic TTH is difficult to treat, so we assumed that all should 
go to levels 2 or 3 (ie, "specialists"). 
Note that those who see a specialist would see a GP first. 
MOH 21.6 100 Current care: 21.6% had seen a GP (2 times in a year) (Eurolight data [21]) 
Target care: With consumer education, 100% see a GP (we assumed 2 visits 
in a year) 
Specialist 
visits 
Migraine 5.8 5.0 Current care: 5.8% had seen a specialist (2 times in a year) 
Target care: With consumer education and provider training, 5.0% (10% of 
50%) see a specialist (we assumed 2 visits in a year) 
TTH 2.5 2.25 Current care: 2.5% had seen a specialist (2 times in a year) 
Target care: With consumer education and provider training, 2.25% see a 
specialist (we assumed 2 visits in a year) 
MOH 29.6 100 Current care: 29.6 % saw a GP (2 times in a year) 
Target care: With consumer education and provider training, 100% see a 




Migraine 8.5 1.0 Current care: All those seeing a specialist had MRI (one in a year) 
Target care: With provider training, we assumed 1% have MRI (one in a 
year) 
TTH 1.0 0.5 Current care: 1% had an MRI 
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Target care: We assumed 0.5% have MRI examination (one in a year) – half 
the current estimate 
MOH 0 0 Current care: Nobody had an MRI 
Target care: Nobody has an MRI 
Doctor visits  
(years 2-5) 
Migraine 24.6 50.0 Current care: 24.6% with migraine had seen a doctor (Eurolight data [21]), 
of whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 50% see a doctor (expert assumption 
based on estimated need for professional care) 
TTH 9.4 2.25 Current care: 9.4% with TTH had seen a doctor (Eurolight data [21]), of 
whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 3% (Stovner 2007 [38]) x 75% = 
2.25% see a doctor (expert assumption based on estimated need for 
professional care).  
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2% with MOH had seen a doctor (Eurolight data [21]), of 
whom all saw a GP only after year 1. We assumed 2 visits per year. 
Target care: With consumer education, 100% see a doctor 
GP visits  Migraine 24.6 50.0 Current care: 24.6% saw a GP. We assumed 2 visits each year. 
Target care: With consumer education, 50% see a GP. We assumed 2 visits 
each year. 
TTH 9.4 0 Current care: 9.4% saw a GP. We assumed 2 visits each year. 
Target care: Chronic TTH is difficult to treat, so we assumed that all should 
go to levels 2 or 3 (ie, "specialists"). 
Note that those who see a specialist would see a GP first. 
MOH 51.2 100 Current care: 51.2 % saw a GP. We assumed 2 visits each year. 




Migraine 0 0 Current care: No visits after year 1 
Target care: No visits after year 1 
TTH 0 2.25 Current care: No visits after year 1 
Target care: With consumer education and provider training, 2.25% see a 
specialist (we assumed 2 visits in a year). 
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MOH 0 0 Current care: No visits after year 1 




Migraine 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
TTH 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
MOH 0 0 Current care: nobody had an MRI after year 1 
Target care: nobody had an MRI after year 1 
Lost productivity We assumed that lost work productivity is correlated with disease-related disability, and reduced disability would 
bring reduced lost productivity. In our baseline scenario, all lost productivity was explained by disease-related 
disability. 
Days lost 
from work in 
12 months 
Migraine 7.6 2.4 Current care: based on Eurolight data [16] 
Target care: we assumed 69% decrease in lost productivity (equal to the 
gain in HLYs reported for migraine [see table 4]): 7.6-(7.6*0.69) = 2.4 days 
 TTH 3.2 0.8 Current care: based on Eurolight data [16] 
Target care: we assumed 76% decrease in lost productivity (equal to the 
gain in HLYs reported for TTH [see table 4]): 3.2-(3.2*0.76) = 0.8 days  
 MOH 22.8 7.1 (if revert 
to migraine); 
5.5 (if revert 
to TTH) 
Current care: based on Eurolight data [16] 
Target care:  
for individuals reverting to migraine, we assumed 69% decrease in lost 
productivity (equal to the gain in HLYs reported for migraine [see table 4]): 
22.8-(22.8*0.69 ) = 7.1 days 
for individuals reverting to TTH, we assumed 76% decrease in lost productivity 
(equal to the gain in HLYs reported for TTH [see table 4]): 22.8-(22.8*0.76 ) 




Table 4: Epidemiological data, disability weights, prevalence, frequency and duration of attacks 
 
 Luxembourg Russia Spain   
  Value Value Value Source Specification 
Population, 
overall 
 586,869 143,500,000 46,064,604 [29] 2016 values 
Proportion 18-
65 yrs old, % 
 70 70.6 66 [30]  
DW (% ictal 
disability) 
migraine 44.1 44.1 44.1 [26] 2015 values 
 TTH 3.7 3.7 3.7 [26] 2015 values 
 MOH 21.7 21.7 21.7 [26] 2015 values 
Prevalence % migraine 30.358 17.888 35.432 [1]  
 TTH 31.037 26.334 25.821 [1]  
 MOH 3.500 7.1 7.000 [1]  
Mean frequency 
days/month 
migraine 4.4/30 4.4/30 4.4/30 [26]  
 TTH 3.5/30 3.5/30 3.5/30 [26]  
 MOH 23.1/30 23.1/30 23.1/30 [26]  
Mean duration, 
hours (current) 
migraine 15 15 15 [26]  
 TTH 7.4 7.4 7.4 [26]  
Mean duration, 
hours (target) 
migraine 2 2 2 expert opinion  
 TTH 2 2 2 expert opinion  
YLDs (current) migraine 0.00040 0.00024 0.00047 [26] 
  TTH 0.00005 0.00003 0.00006 [26] 
 MOH 0.00020 0.00017 0.00017 [26] 
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YLDs (target) migraine 0.00005 0.00005 0.00005  
 TTH 0.00585 0.01186 0.01170  
DW: disability weight; TTH: tension type headache; MOH: medication-overuse headache; YLDs: years of healthy life lost to disability. 









ASA 1 g = 0.39 [28] 
Sumatriptan 50 mg = 0.35 [29] 




ASA 1 g = 0.75 (expert opinion) 
Paracetamol 1 g = 0.59 [31] 




Efficacy = reverted to migraine 85%*2/3 + reverted to TTH 85%*1/3 + 





ASA 1 g = 0.635 (expert opinion) 
Sumatriptan 50 mg = 0.005 (expert opinion) 




Analgesic ASA 1 g =0.1 (expert opinion)  
Paracetamol 1 g = 0.456 (expert opinion)  
Amitriptyline 100 mg = 0 (expert opinion) 
Treatment efficacy (weighted by medications uptake) 
Efficacy*uptake 
calculations 
One medication = [proportion with effect] * [effect] * [uptake];  
Combination of two medications = [(proportion with effect)medication A * 
(effect)medication A * (uptake)medication A] + [(proportion with effect)medication B * 
(effect)medication B * (uptake)medication B] 
Healthy life years (HLYs) 
HLYs untreated = DW * proportion of time with headache (= number/year * duration in 
years);  
HLYs treated = HLYs untreated - HLY gained from treatment;  
HLYs gained = HLYs untreated * efficacy;  
Total HLYs gained per person = sum of (gains from each treatment * probability of having 
each treatment) 
HLYs gained across the population = HLY gained per person affected * prevalence. 
HLYs MOH treated = unchanged in 15% + migraine treated HLYs in 2/3*42.5% + TTH 




























CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING 
Primary analysis 
Medications       
acute non-specific ASA 1 g  7,568 35,364 855,296 3,996,867 508,399 2,375,791 
acute-specific sumatriptan 50 mg 3,635 16,986 1,207,420 5,642,371 251,626 1,175,870 
prophylaxis amitriptyline 100 mg/day 695 3,249 195,304 912,670 20,816 97,276 
Total medications 11,898 55,599 2,258,020 10,551,908 780,841 3,648,937 
Health-care provision      
GP visits 1,868,796 6,153,787 133,597,931 493,496,811 185,508,849 725,403,433 
specialist visits 708,809 708,809 126,073,602 126,073,602 125,445,228 125,445,229 
MRI 361,613 361,613 77,008,823 77,008,823 73,240,116 73,240,116 
Total health-care provision 2,939,218 7,224,209 336,680,356 696,579,236 384,194,193 924,088,778 
Secondary analyses 
Total lost productivity 120,885,706 564,908,477 2,045,525,786 9,558,904,021 4,136,426,354 19,329,847,995 
Sensitivity analysis: disability 
accounts for 20% lost productivity 
24,177,141 112,981,695 409,105,157 1,911,780,804 827,285,271 3,865,969,599 





Medications       
acute non-specific ASA 1 g  16,564 77,405 1,498,933 7,004,632 370,931 1,733,392 
acute-specific sumatriptan 50 mg 153,854 718,974 50,269,478 234,913,251 10,313,113 48,193,995 
prophylaxis amitriptyline 100 
mg/day 
30,050 140,425 7,857,564 36,719,020 899,802 4,204,845 
Total medications 200,468 936,804 59,625,975 278,636,903 11,583,846 54,132,232 
Health-care provision      
GP visits 4,357,297 12,893,134 373,410,366 1,104,912,154 399,420,967 1,181,876,886 
specialist visits 611,042 611,042 74,160,942 74,160,942 46,119,569 46,119,569 
MRI  62,347 62,347 9,059,861 9,059,861 5,385,303 5,385,303 
Total health-care provision 5,030,686 13,566,523 456,631,169 1,188,132,957 450,925,839 1,233,381,758 
Secondary analyses 
Total lost productivity 5,431,622 373,419,228 1,296,237,360 6,057,419,858 2,621,228,447 12,249,208,158 
Sensitivity analysis: disability 
accounts for 20% lost productivity 
1,086,324 74,683,846 259,247,472 1,211,483,972 524,245,689 2,449,841,632 
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CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING 
Primary analysis 
Medications       
acute ASA 1 g or 
paracetamol 1 g 




- - - - - - 
Total medications 21,135 98,765 3,439,657 16,073,791 1,012,106 4,729,652.69 
Health-care provision      
GP visits 710,354 1,658,990 87,659,562 204,723,838 46,415,831 108,401,488 
specialist visits 324,834 324,834 56,770,353 56,770,352 17,476,479 17,476,480 
MRI  66,288 66,288 13,870,685 13,870,685 4,081,397 4,081,397 
Health-care 
provision 




46,505,330 217,323,093 1,133,152,091 5,295,309,478 1,134,307,720 5,300,709,824 
Sensitivity analysis: 
disability accounts 
for 20% lost 
productivity 










TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING 
Primary analysis 
Medications       
acute ASA 1 g or 
paracetamol 1 g 




3,122 14,590 1,175,568 5,493,524 66,639 311,410 
Total medications 34,306 160,314 5,239,069 24,482,585 564,415 2,637,558 
Health-care provision      
GP visits 222,734 222,734 13,742,996 13,742,996 14,553,862 14,553,862 
specialist visits 281,115 281,115 49,129,551 49,129,551 15,124,295 15,124,295 
MRI  31,870 31,870 6,668,783 6,668,783 1,962,264 1,962,264 
Total health-care 
provision 




45,491,467 146,579,889 764,287,428 3,571,575,691 765,066,876 3,575,218,111 
Sensitivity analysis: 
disability accounts 
for 20% lost 
productivity 


























Cost (euros)  
5-year estimate 
CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING 
Primary analysis 
Total health-care costs  571,570 2,670,992 168,632,151 788,031,399 89,782,290 419,559,753 
Secondary analyses 
Total lost productivity 64,622,955 301,988,186 3,764,597,029 17,592,260,104 3,789,174,825 17,707,114,095 
Sensitivity analysis: disability 
accounts for 20% lost 
productivity 
12,924,591 60,397,637 752,919,406 3,518,452,021 757,834,965 541,422,818.96 
TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING 
Primary analysis 
Total health-care costs 266,932 2,670,992 86,693,089 405,123,672 40,755,568 190,453,998 
Secondary analyses 
Total lost productivity 9,011,897 42,113,311 520,108,800 2,430,509,620 523,504,417 2,446,377,605 
Sensitivity analysis: disability 
accounts for 20% lost 
productivity 
1,802,379 8,422,662 104,021,760 486,101,924 104,700,883 489,275,521 
 












































CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING 
A. Acute management 
(non-specific drugs) 
ASA 1 g 
0.2146 0.0399 0.0313 0.0086 79,193 0.0026 11,507,795 0.0015 6,840,387 0.0030 
B. Acute management 
(specific drugs) 
sumatriptan 50 mg 
0.0015 0.0399 0.0398 0.0001 624 1.83579E-05 90,613 1.08171E-05 53,861 0.0000 
C. Acute stepped-care 
management ASA 1 g 
+ sumatriptan 50 mg 
0 0.0399 0.0399 0 0 0 0 0 0 0 
D. Prophylaxis + acute 
management 
amitriptyline 100 
mg/day + ASA 1 g + 
sumatriptan 50 mg 
0.0031 0.0399 0.0397 0.0001 873 3.72807E-05 126,858 2.19671E-05 75,406 0.00004 
Total 
 
   80,690 0.002656 11,725,266 0.001533 6,969,654 0.00304 
HLYs FOR OVERALL POPULATION    1,090 158,406 94,159 
TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING 
A. Acute management 
(non-specific drugs) 
ASA 1 g  
0.1386 0.0399 0.0343 0.0055 51,132 0.0017 7,430,230 0.0010 4,416,628 0.0020 
B. Acute management 
(specific drugs) 
sumatriptan 50 mg 
0 0.0399 0.0399 0 0 0  0  0 
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C. Acute stepped-care 
management ASA 1 g 
+ sumatriptan 50 mg 
0.1052 0.0399 0.0357 0.0042 153,854 0.0013 50,269,478 0.0008 10,313,113 0.0015 
D. Prophylaxis + acute 
management 
amitriptyline 100 
mg/day + ASA 1 g + 
sumatriptan 50 mg  
0.2020 0.0399 0.0318 0.0081 30,679 0.0024 4,458,138 0.0014 2,649,977 0.0029 
Total     235,666 0.0054 62,157,845 0.0032 17,379,718 0.0063 














































CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING 
Acute management 
ASA 1 g or 
paracetamol 1 g  
0.3340 0.0013 0.0009 0.0004 70,890 0.0001 14,833,657 0.00012 4,364,748 0.00011 
Prophylaxis + acute 
management 
amitriptyline 100 
mg/day + ASA 1 g or 
paracetamol 1 g 
0.3340 0.0013 0.0009 0.0004 0 0.0001 0 0.00012 0 0.00011 
Total     70,890 0.0002 14,833,657 0.0026 4,364,748 0.00022 
HLYs FOR OVERALL POPULATION    112 23,398 6,885 
TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING 
Acute management 
ASA 1 g or 
paracetamol 1 g  
0.4847 0.0013 0.0007 0.0006 96,263 0.0002 2,0142,825 0.00017 5,926,950 0.00016 
Prophylaxis + acute 
management 
amitriptyline 100 
mg/day + ASA 1 g or 
paracetamol 1 g 
0.4886 0.0013 0.0007 0.0006 3,188 0.0002 666,981 0.00017 196,257 0.00017 
Total     99,451 0.0004 20,809,806 0.0026 6,123,207 0.00033 




Table 11: Healthy Life Years (HLYs) potentially gained in 1 year by each element of the proposed intervention (MOH) 
 






































CURRENT CARE: NO CONSUMER EDUCATION AND HEALTH CARE PROFESSIONAL TRAINING 
No treatment coverage  0.1671 0 0 0 0 0 0 0 0 
HLYs FOR OVERALL POPULATION    0  0  0 
TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH CARE PROFESSIONAL TRAINING 
Treatment coverage  0.1671 0.2318 0.0647 6,110 0.0046 3,057,059 0.0046 904,478 0.0046 





Appendix 1: Unit costs 
 
Luxembourg 












MEDICINES    [5,17,19]. Costs actualised to 2020 
values using appropriate consumer 
price index [23] 
A. Acute management (non-specific drugs)    
ASA 1 g 0.10 0.07 0.07  
Paracetamol 1 g 0.297 0.23 0.23  
With consumer education 0.33 0.21 0.08  
B. Acute management (specific drugs)    
Sumatriptan 50 mg 6.06 13.85 4.86  
With consumer education and 
provider training 
6.07 14.09 4.87  
C. Acute stepped-care management     
ASA 1 g + sumatriptan 50 mg 6.16 17.35 4.94  
With consumer education and 
provider training 
7.82 17.59 6.07  
D. Prophylaxis + acute management 
   
Amitriptyline 100 mg + ASA 1 g + 
sumatriptan 50 mg 
0.83 1.60 0.29  
With consumer education and 
provider training 




    
One GP visit 38.76 22.86 41.13 [20] 
One specialist visit 48.92 40.85 42.74 [20] 
EXAMINATION 
    
One MRI 49.91 49.91 49.91 [7] 
PRODUCTIVITY     
Daily wages 205.01 23.87 81.21 [23] 
 
